Funds holding “Ligand Pharmaceuticals Inc”
Which closed-end funds own a security? Searches the latest N-PORT snapshot of every active fund. Enter a ticker (issuer-level: matches the vendor-mapped ticker), a CUSIP or ISIN (security-level: one specific bond or share class), or part of a name.
15 positions across 10 funds, 3 distinct securities (bonds, share classes and derivatives of the same issuer are listed separately). Weights are percent of net assets from each fund’s latest N-PORT; report dates differ by fund.
| Fund | Position | Identifier | Type | Weight | Value (USD) | Report date | Coverage |
|---|---|---|---|---|---|---|---|
| BCV Bancroft Fund U.S. Equity | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 2.32% | $4.5M | Jun 30, 2026 | full (88 positions) |
| GCV Gabelli Convertible & Income Securities Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 2.20% | $2.1M | Jun 30, 2026 | full (121 positions) |
| ECF Ellsworth Growth & Income Fund U.S. Equity | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 1.91% | $4.5M | Jun 30, 2026 | full (99 positions) |
| ASG Liberty All Star Growth Fund U.S. Equity | Ligand Pharmaceuticals Inc | 53220K504 | EC | 1.27% | $5.1M | Jun 30, 2026 | full (119 positions) |
| NCZ Virtus Convertible & Income Fund II Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAJ7 | DBT | 0.41% | $1.9M | Jul 31, 2026 | full (211 positions) |
| NCV Virtus Convertible & Income Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAJ7 | DBT | 0.39% | $2.3M | Jul 31, 2026 | full (210 positions) |
| ACV Virtus Diversified Income & Convertible Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAJ7 | DBT | 0.37% | $1.4M | Jul 31, 2026 | full (281 positions) |
| NIE Virtus Equity & Convertible Income Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAJ7 | DBT | 0.24% | $1.9M | Jul 31, 2026 | full (164 positions) |
| AVK Advent Convertible & Income Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAJ7 | DBT | 0.22% | $1.6M | Jul 31, 2026 | full (466 positions) |
| NCZ Virtus Convertible & Income Fund II Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 0.20% | $946K | Jul 31, 2026 | full (211 positions) |
| NCV Virtus Convertible & Income Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 0.20% | $1.2M | Jul 31, 2026 | full (210 positions) |
| ACV Virtus Diversified Income & Convertible Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 0.19% | $707K | Jul 31, 2026 | full (281 positions) |
| NFJ Virtus Dividend, Interest & Premium Strategy Fund U.S. Equity | LIGAND PHARMACEUTICALS INC | 53220KAJ7 | DBT | 0.13% | $1.9M | Jul 31, 2026 | full (170 positions) |
| NIE Virtus Equity & Convertible Income Fund Convertible Securities | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 0.12% | $946K | Jul 31, 2026 | full (164 positions) |
| NFJ Virtus Dividend, Interest & Premium Strategy Fund U.S. Equity | LIGAND PHARMACEUTICALS INC | 53220KAG3 | DBT | 0.06% | $946K | Jul 31, 2026 | full (170 positions) |
Matching position names
LIGAND PHARMACEUTICALS INC · 14Ligand Pharmaceuticals Inc · 1
Historical holdings reports are not a real-time portfolio. Security-level matching (CUSIP/ISIN) distinguishes a company’s bonds, common shares, preferreds and derivatives; issuer-level matching groups them by name or ticker and is labelled as such. See the overlap tool to compare two portfolios.